97 related articles for article (PubMed ID: 15023348)
1. Design of hypoxia-targeting protein tyrosine kinase inhibitor using an innovative pharmacophore 2-methylene-4-cyclopentene-1,3-dione.
Hori H; Nagasawa H; Uto Y; Ohkura K; Kirk KL; Uehara Y; Shimamura M
Biochim Biophys Acta; 2004 Mar; 1697(1-2):29-38. PubMed ID: 15023348
[TBL] [Abstract][Full Text] [Related]
2. TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity.
Hori H; Nagasawa H; Ishibashi M; Uto Y; Hirata A; Saijo K; Ohkura K; Kirk KL; Uehara Y
Bioorg Med Chem; 2002 Oct; 10(10):3257-65. PubMed ID: 12150871
[TBL] [Abstract][Full Text] [Related]
3. An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase.
Ohkura K; Kawaguchi Y; Tatematsu Y; Uto Y; Hori H
Anticancer Res; 2016 Jul; 36(7):3645-9. PubMed ID: 27354635
[TBL] [Abstract][Full Text] [Related]
4. Design of antiangiogenic hypoxic cell radiosensitizers: 2-nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety.
Uto Y; Nagasawa H; Jin CZ; Nakayama S; Tanaka A; Kiyoi S; Nakashima H; Shimamura M; Inayama S; Fujiwara T; Takeuchi Y; Uehara Y; Kirk KL; Nakata E; Hori H
Bioorg Med Chem; 2008 Jun; 16(11):6042-53. PubMed ID: 18474428
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17.
Liang BC; Ullyatt E
Clin Cancer Res; 1998 Mar; 4(3):773-81. PubMed ID: 9533547
[TBL] [Abstract][Full Text] [Related]
6. Interactive Analysis of TX-1123 with Cyclo-oxygenase: Design of COX2 Selective TX Analogs.
Ohkura K; Tatematsu Y; Kawaguchi Y; Uto Y; Hori H
Anticancer Res; 2017 Jul; 37(7):3849-3854. PubMed ID: 28668885
[TBL] [Abstract][Full Text] [Related]
7. Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.
Burger AM; Kaur G; Alley MC; Supko JG; Malspeis L; Grever MR; Sausville EA
Cancer Res; 1995 Jul; 55(13):2794-9. PubMed ID: 7796405
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between Radiosensitizing Activity and the Stereo-structure of the TX-2036 Series of Molecules.
Ohkura K; Tabata A; Uto Y; Hori H
Anticancer Res; 2019 Aug; 39(8):4479-4483. PubMed ID: 31366548
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells.
Tallett A; Chilvers ER; Hannah S; Dransfield I; Lawson MF; Haslett C; Sethi T
Cancer Res; 1996 Sep; 56(18):4255-63. PubMed ID: 8797601
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
McLeod HL; Brunton VG; Eckardt N; Lear MJ; Robins DJ; Workman P; Graham MA
Br J Cancer; 1996 Dec; 74(11):1714-8. PubMed ID: 8956783
[TBL] [Abstract][Full Text] [Related]
11. Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s).
Sauro MD; Thomas B
J Pharmacol Exp Ther; 1993 Dec; 267(3):1119-25. PubMed ID: 8263773
[TBL] [Abstract][Full Text] [Related]
12. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
13. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.
Levitzki A
FASEB J; 1992 Nov; 6(14):3275-82. PubMed ID: 1426765
[TBL] [Abstract][Full Text] [Related]
14. A tyrphostin-derived inhibitor of protein tyrosine kinases: isolation and characterization.
Ramdas L; Obeyesekere NU; McMurray JS; Gallick GE; Seifert WE; Budde RJ
Arch Biochem Biophys; 1995 Nov; 323(2):237-42. PubMed ID: 7487083
[TBL] [Abstract][Full Text] [Related]
15. Tyrphostins are inhibitors of guanylyl and adenylyl cyclases.
Jaleel M; Shenoy AR; Visweswariah SS
Biochemistry; 2004 Jun; 43(25):8247-55. PubMed ID: 15209521
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action.
Aflalo E; Iftach S; Segal S; Gazit A; Priel E
Cancer Res; 1994 Oct; 54(19):5138-42. PubMed ID: 7923131
[TBL] [Abstract][Full Text] [Related]
17. Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents.
Wells G; Seaton A; Stevens MF
J Med Chem; 2000 Apr; 43(8):1550-62. PubMed ID: 10780912
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinases as targets for cancer therapy.
Levitzki A
Eur J Cancer; 2002 Sep; 38 Suppl 5():S11-8. PubMed ID: 12528768
[TBL] [Abstract][Full Text] [Related]
19. Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60(c-src) kinase activity.
Wijetunge S; Lymn JS; Hughes AD
Br J Pharmacol; 2000 Apr; 129(7):1347-54. PubMed ID: 10742290
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
